Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer
| Status: | Archived |
|---|---|
| Conditions: | Prostate Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | August 2010 |
| End Date: | December 2011 |
A Phase II Study of Bafetinib (INNO-406) as Treatment for Patients With Hormone-Refractory Prostate Cancer
This is a Phase II open-label study evaluating the preliminary efficacy and safety of
bafetinib administered as 240 mg orally twice daily in subjects with Hormone Refractory
Prostate Cancer.
We found this trial at
1
site
Click here to add this to my saved trials
